<DOC>
	<DOCNO>NCT01548079</DOCNO>
	<brief_summary>In open-label trial , 20 otherwise healthy morbidly obese patient schedule bariatric surgery administer 20 mg/kg/day ursodeoxycholic acid three week day surgery . The maximum dose 3 g/day . Twenty patient serve control . Serum day 1 21 analyzed routine liver test , bile acid , complete lipid profile include FA addition 7α-hydroxy-4-cholesten-3-one fibroblast growth factor 19 ( FGF-19 ) , marker bile acid synthesis intestinal stimulation . For evaluation insulin resistance possible pre-diabetes , plasma take estimation homeostasis model assessment ( HOMA ) index oral glucose tolerance test ( OGTT ) perform day 1 21 . At surgery , liver biopsy ( 0.5-1 g ) white adipose tissue ( WAT ) specimen ( 1 cm2 ) take immediately frozen liquid nitrogen messenger ribonucleic acid ( mRNA ) protein preparation quantitative real-time polymerase chain reaction ( RT-PCR ) Western analysis , respectively , histopathological Non-alcoholic fatty liver disease ( NAFLD ) grading , measure hepatic white adipose tissue ( WAT ) lipase activity . In patient randomization , abdominal ultrasound perform detection NAFLD gallstone blood sample take analysis polymorphisms hepatic lipid synthesis , storage , fatty acid ( FA ) oxidation export gene . Six month operation , HOMA , OGTT abdominal ultrasound repeat .</brief_summary>
	<brief_title>Ursodeoxycholic Acid Bariatric Surgery</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Obesity , Morbid</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>BMI ≥ 35 kg/m2 Patients eligible bariatric surgery Patients give write consent participate study Chronic liver disease NAFLD ( viral hepatitis , autoimmune liver disease , hemochromatosis , homozygous alpha1antitrypsin deficiency Wilson disease ) Partial ileal bypass Inflammatory bowel disease Uncontrolled diabetes mellitus ( fast blood glucose &gt; 6.7 mmol/L ) , hypothyroidism hyperthyroidism , significant endocrine disease . A subject euthyroid stable replacement dose thyroid hormone acceptable provide TSH within normal range . Other serious disease Known hypersensitivity ursodeoxycholic acid Patients comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>ursodeoxycholic acid</keyword>
	<keyword>fatty liver disease</keyword>
	<keyword>morbid obesity</keyword>
	<keyword>bariatric surgery</keyword>
	<keyword>NAFLD</keyword>
</DOC>